Clinical Perspectives on Dual Checkpoint Blockade for mNSCLC
Dual checkpoint blockade is becoming a more common approach for patients with mNSCLC and no targetable driver mutation, and a new regimen was recently approved. Join us to hear from a thoracic oncologist, Christine Bestvina, MD, about how these regimens are changing patients’ perspectives about their likely outcomes, the clinical implications of emerging safety and efficacy data, and how to educate patients about participating in clinical trials.
Or just listen to the episode using the player below:
Podcast: Play in new window | Download
Subscribe: Apple Podcasts | Android | Blubrry | Email | RSS